<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04058535</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-L9-01</org_study_id>
    <nct_id>NCT04058535</nct_id>
  </id_info>
  <brief_title>Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular Age-related Macular Degeneration</brief_title>
  <official_title>A Phase I Clinical Study of ALT-L9 in Patients With Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alteogen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alteogen, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, efficacy and pharmacokinetics of repeated intravitreal administration&#xD;
      of ALT-L9 2 mg/50uL compared with Eylea in patients with neovascular Age-related macular&#xD;
      degeneration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrences of adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <description>Check the adverse events in study eye at the assessment points after triple administration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>ALT-L9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection of ALT-L9 50 ul, every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eylea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal injection of Eylea 50 ul, every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Eylea</intervention_name>
    <description>Aflibercept</description>
    <arm_group_label>Eylea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALT-L9</intervention_name>
    <description>Aflibercept biosimilar</description>
    <arm_group_label>ALT-L9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 50yeras old or more at the time of consent.&#xD;
&#xD;
          2. Patients with any history of anti-VEGF treatment(Aflibercept, Bevacizumab,&#xD;
             Ranibizumab) for neovascular AMD in the study eye.&#xD;
&#xD;
          3. Patients who were treated with the last anti-VEGF at least 8 weeks prior to study drug&#xD;
             administration.&#xD;
&#xD;
          4. Patients with untreated active primary subfoveal CNV lesions secondary to AMD,&#xD;
             including juxtafoveal lesions that affect the fovea as evidenced by FA in the study&#xD;
             eye at the start of the screening visit.&#xD;
&#xD;
          5. Patients with subretinal, intraretinal, or subretinal pigment epithelium fluid as&#xD;
             assessed by SD-OCT in the study eye at the start of the screening visit.&#xD;
&#xD;
          6. Patients who have CNV which is at least 50% of total lesion size in the study eye at&#xD;
             the start of the screening visit.&#xD;
&#xD;
          7. Patients with ETDRS best-corrected visual acuity of 20/40 to 20/320 (letter score of&#xD;
             73 to 25) in the study eye at the start of the administration of the study drug.&#xD;
&#xD;
          8. Patients with ETDRS best-corrected visual acuity of 20/400 (letter score 20) or better&#xD;
             in the fellow eye at the start of the administration of the study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have received any prior ocular (in the study eye) or systemic treatment&#xD;
             for neovascular AMD within 8 weeks from the screening date except dietary supplements&#xD;
             or vitamins.&#xD;
&#xD;
          2. Patients who have received any surgery for neovascular AMD.&#xD;
&#xD;
          3. Patients with any current or history of macular or retinal disease other than&#xD;
             neovascular AMD (eg, diabetic macular edema, retinal vein occlusion, pathological&#xD;
             myopia, angioid streaks, ocular histoplasmosis, trauma, retinal detachment, epiretinal&#xD;
             membrane, macular hole, central serous chorioretinopathy, Choroidal rupture, Multiple&#xD;
             network choroiditis, proliferative diabetic retinopathy) in the study eye.&#xD;
&#xD;
          4. Patients with scar, fibrosis, or atrophy involving the center of the fovea in the&#xD;
             study eye that might interfere with visual acuity.&#xD;
&#xD;
          5. Patients with hemorrhage under the fovea or subretinal hemorrhage 50% or more of the&#xD;
             total lesion area in the study eye.&#xD;
&#xD;
          6. Patients with retinal pigment epithelial tears or rips involving the macula in the&#xD;
             study eye.&#xD;
&#xD;
          7. Patients with a history of any vitreous hemorrhage or rhegmatogenous retinal&#xD;
             detachment in the study eye within 4 weeks before the start of the administration of&#xD;
             the study drug.&#xD;
&#xD;
          8. Patients who have received panretinal photocoagulation in the study eye.&#xD;
&#xD;
          9. Patients who have received vitreous surgery in the study eye.&#xD;
&#xD;
         10. Patients with a history of corneal transplant or corneal dystrophy in the study eye.&#xD;
&#xD;
         11. Patients who have received cataract surgery or Lasik in the study eye within 90 days&#xD;
             before the start of the administration of the study drug.&#xD;
&#xD;
         12. Patients who have received trabeculectomy or other filtration surgery in the study&#xD;
             eye.&#xD;
&#xD;
         13. Patients with poorly controlled glaucoma (defined as intraocular pressure â‰¥ 25 mmHg&#xD;
             despite treatment with antiglaucoma medication) in the study eye.&#xD;
&#xD;
         14. Patients with significant media opacities, including cataract, in the study eye that&#xD;
             might interfere with visual acuity, assessment of safety, or fundus photography&#xD;
             considered by the principal investigator or investigator.&#xD;
&#xD;
         15. Patients with any diseases in the study eye that could have compromised visual acuity&#xD;
             such as amblyopia and anterior ischemic optic neuropathy considered by the principal&#xD;
             investigator or investigator.&#xD;
&#xD;
         16. Patients with cataract in the study eye that could have required medical or surgical&#xD;
             intervention during the course of the study considered by the principal investigator&#xD;
             or investigator.&#xD;
&#xD;
         17. Patients with aphakia with absence of posterior capsule (in the study eye.&#xD;
&#xD;
         18. Patients who have received therapeutic radiation in the region of the study eye.&#xD;
&#xD;
         19. Patients who use topical ocular corticosteroids for 30, or more, consecutive days&#xD;
             within 90 days before the screening visit, or have a plan or actual use for 30 or more&#xD;
             consecutive days during the course of the study in the study eye.&#xD;
&#xD;
             Criteria for fellow eye or either eye:&#xD;
&#xD;
         20. Patients with any active intraocular or periocular infection or intraocular&#xD;
             inflammation in either eye (eg, infectious blepharitis, infectious conjunctivitis,&#xD;
             keratitis, scleritis, endophthalmitis).&#xD;
&#xD;
         21. Patients with a history of uveitis in either eye.&#xD;
&#xD;
         22. Patients with a concurrent or history of scleromalacia in either eye.&#xD;
&#xD;
         23. Patients who have received anti-VEGF medication in the fellow eye within 8 weeks&#xD;
             before the start of the administration of the study drug.&#xD;
&#xD;
             Other criteria:&#xD;
&#xD;
         24. Patients who use systemic corticosteroids for 30 or more consecutive days within 90&#xD;
             days before the Screening Visit, or have a plan or actual use for 30 or more&#xD;
             consecutive days during the course of the study. Inhaled steroids were permitted.&#xD;
&#xD;
         25. Patients who use steroid(except systemic or inhaled steroid) within 6 months, or have&#xD;
             a plan for use of steroid during the course of the study.&#xD;
&#xD;
         26. Patients with poorly controlled hypertension. (defined as systolic BP is 160 mmHg or&#xD;
             more or diastolic BP is 100 mmHg or more despite medication)&#xD;
&#xD;
         27. Patients with a serious liver, kidney or cardiovascular disorders considered by the&#xD;
             principal investigator or investigator.&#xD;
&#xD;
         28. Patients with a concurrent or history of malignancy within 5 years before informed&#xD;
             consent.&#xD;
&#xD;
         29. Patients with drug abuse (defined as use of illegal drugs) or alcohol dependence or a&#xD;
             history of these conditions.&#xD;
&#xD;
         30. Patients with a history of clinically significant drug hypersensitivity.&#xD;
&#xD;
         31. Patients with a history of allergy to aflibercept, fluorescein, indocyanine green and&#xD;
             povidone iodine.&#xD;
&#xD;
         32. Patients with any contraindications described in aflibercept package insert.&#xD;
&#xD;
         33. Females who are pregnant, breastfeeding, or of childbearing potential, unwilling to&#xD;
             practice adequate contraception throughout the study.&#xD;
&#xD;
         34. Patients with type 1 diabetes or increase of HbA1c(&gt;12%).&#xD;
&#xD;
         35. Patients who have received any other investigational drug within 12 weeks before&#xD;
             screening visit.&#xD;
&#xD;
         36. Other patients considered by the principal investigator or investigator to be&#xD;
             inappropriate as subjects.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alteogen</name>
      <address>
        <city>Daejeon</city>
        <state>Korea, Republic of(KOR)</state>
        <zip>34054</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 14, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>September 1, 2019</last_update_submitted>
  <last_update_submitted_qc>September 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

